Citation Impact
Citing Papers
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: Executive Summary
2014 Standout
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
2012 Standout
Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial
2008
Predicting Low Toxicity and Scalable Solvent Systems for High‐Speed Roll‐to‐Roll Perovskite Manufacturing
2021 StandoutNobel
Saturated but not mono-unsaturated fatty acids induce apoptotic cell death in neonatal rat ventricular myocytes
1997
Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism
2013 Standout
Antithrombotic Therapy for Venous Thromboembolic Disease
2008 Standout
DisGeNET: a comprehensive platform integrating information on human disease-associated genes and variants
2016 Standout
Current concepts in the mechanisms and management of drug-induced QT prolongation and torsade de pointes
2007
The influence of drug-like concepts on decision-making in medicinal chemistry
2007 Standout
Heparin and Low-Molecular-Weight Heparin Mechanisms of Action, Pharmacokinetics, Dosing, Monitoring, Efficacy, and Safety
2001 Standout
Effects of SanOrg123781A, a Synthetic Hexadecasaccharide, in a Mouse Model of Electrically Induced Carotid Artery Injury: Synergism with the Antiplatelet Agent Clopidogrel
2004
The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements
2009
New Antithrombotic Drugs
2008
Marine natural products
1990 Standout
New Antithrombotic Drugs
2012
Antithrombotic Therapy for VTE Disease
2016 Standout
Dietary Fats and Hypertension Focus on Fish Oil
1997
hERGAPDbase: a database documenting hERG channel inhibitory potentials and APD-prolongation activities of chemical compounds
2011
Discovery of new binding elements in DPP-4 inhibition and their applications in novel DPP-4 inhibitor design
2008
A structure-based computational workflow to predict liability and binding modes of small molecules to hERG
2020 StandoutNobel
Antithrombotic Therapy for VTE Disease
2012 Standout
How to improve R&D productivity: the pharmaceutical industry's grand challenge
2010 Standout
Abnormal membrane concentrations of 20 and 22-carbon essential fatty acids: A common link between risk factors and coronary and peripheral vascular disease?
1995
Platelet Activation and Atherothrombosis
2007 Standout
Designing antimicrobial peptides: form follows function
2011 Standout
Helix D Elongation and Allosteric Activation of Antithrombin
2002
Heparin and Low-Molecular-Weight Heparin
2004
QTc interval prolongation during favipiravir therapy in an Ebolavirus-infected patient
2017
The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates
2007
Dabigatran versus Warfarin in Patients with Atrial Fibrillation
2009 Standout
Small-molecule inhibitors of protein–protein interactions: progressing towards the dream
2004 Standout
In vitro pharmacologic testing using human induced pluripotent stem cell-derived cardiomyocytes
2009 StandoutNobel
Prevention of Venous Thromboembolism
2004 Standout
Heparin and Low-Molecular-Weight Heparin
1998
How were new medicines discovered?
2011 Standout
Dipeptidyl peptidase‐4 inhibitors in the treatment of type 2 diabetes: a comparative review
2010
Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes
2009
Analysis of Pharmacology Data and the Prediction of Adverse Drug Reactions and Off‐Target Effects from Chemical Structure
2007
Altered acyl chain compositions of alkylacyl, alkenylacyl, and diacyl subclasses of choline and ethanolamine glycerophospholipids in rat heart by dietary fish oil
1989
Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
2012 Standout
Computational investigations of hERG channel blockers: New insights and current predictive models
2015
Relating protein pharmacology by ligand chemistry
2007 Standout
Trelagliptin (SYR-472, Zafatek), Novel Once-Weekly Treatment for Type 2 Diabetes, Inhibits Dipeptidyl Peptidase-4 (DPP-4) via a Non-Covalent Mechanism
2016
Synergistic action between inhibition of P2Y12/P2Y1 and P2Y12/thrombin in ADP‐ and thrombin‐induced human platelet activation
2004 StandoutNobel
In Vitro Effects of Amino Alcohols on Echinococcus granulosus
2017
Antithrombotic Therapy for Stroke Prevention in Atrial Fibrillation
2005
Assessing the proarrhythmic potential of drugs: Current status of models and surrogate parameters of torsades de pointes arrhythmias
2006
ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)
2011 Standout
Essential fatty acids in growth and development
1991 Standout
Integrins
2002 Standout
Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis
2013 Standout
Reducing safety-related drug attrition: the use of in vitro pharmacological profiling
2012
Oral Apixaban for the Treatment of Acute Venous Thromboembolism
2013 Standout
Pharmacological Promiscuity: Dependence on Compound Properties and Target Specificity in a Set of Recent Roche Compounds
2009
New antithrombotic agents
1999
Acquired QT interval prolongation and HERG: implications for drug discovery and development
2004
Automatic Filtering and Substantiation of Drug Safety Signals
2012
An analysis of the attrition of drug candidates from four major pharmaceutical companies
2015 Standout
In vitroandin vivomodels for testing arrhythmogenesis in drugs
2005
APETx1 from Sea Anemone Anthopleura elegantissima Is a Gating Modifier Peptide Toxin of the Human Ether-a-go-go- Related Potassium Channel
2007
Hemostasis in the Mouse (Mus musculus): A Review
1999
Rings in Drugs
2014 Standout
Fluorine in medicinal chemistry
2007 Standout
What Do Medicinal Chemists Actually Make? A 50-Year Retrospective
2011
The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
2004
Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19)
2020 Standout
Serpin Structure, Mechanism, and Function
2002 Standout
Magnesium in Man: Implications for Health and Disease
2014 Standout
Idraparinux versus Standard Therapy for Venous Thromboembolic Disease
2007
Ranolazine for the Treatment of Chronic Angina and Potential Use in Other Cardiovascular Conditions
2006
Natural Products as Sources of New Drugs over the Nearly Four Decades from 01/1981 to 09/2019
2020 Standout
Alogliptin: a new addition to the class of DPP-4 inhibitors
2009
Effects of a Mediterranean-Style Diet on Cardiovascular Risk Factors
2006 Standout
Oral Rivaroxaban for Symptomatic Venous Thromboembolism
2010 Standout
Nitrile-Containing Pharmaceuticals: Efficacious Roles of the Nitrile Pharmacophore
2010 Standout
Echinococcosis: Advances in the 21st Century
2019 Standout
Guidelines for the Primary Prevention of Stroke
2014 Standout
Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors α and γ
1997 Standout
Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation
2007 Standout
Analysis of Past and Present Synthetic Methodologies on Medicinal Chemistry: Where Have All the New Reactions Gone?
2015 Standout
Dietary Linolenic Acid Is Associated With a Lower Prevalence of Hypertension in the NHLBI Family Heart Study
2005
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
2014 Standout
Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism
2012 Standout
Development of a Synthetic Heparin Pentasaccharide: Fondaparinux.
2002
Extended Prophylaxis of Venous Thromboembolism with Idraparinux
2007
2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation
2015 Standout
Calcitonin Gene‐Related Peptide ( CGRP ) and Migraine Current Understanding and State of Development
2013
Assessing hERG Pore Models As Templates for Drug Docking Using Published Experimental Constraints: The Inactivated State in the Context of Drug Block
2014
Applications of Fluorine in Medicinal Chemistry
2015 Standout
Effect of dietary lipids on the lipid composition and phospholipid deacylating enzyme activities of rat heart
1987
2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes
2014 Standout
Fish Consumption, Fish Oil, Omega-3 Fatty Acids, and Cardiovascular Disease
2002 Standout
Platelet Glycoprotein IIb-IIIa Antagonists as Prototypical Integrin Blockers: Novel Parenteral and Potential Oral Antithrombotic Agents
2000
Triglyceride accumulation protects against fatty acid-induced lipotoxicity
2003 Standout
Gaining Insight into Off-Target Mediated Effects of Drug Candidates with a Comprehensive Systems Chemical Biology Analysis
2009
Works of Peter Hoffmann being referenced
Interspecies Comparison of the Antiplatelet, Antithrombotic, and Hemorrhagic Effects of SR 121566A, a Novel Nonpeptide GP IIb/IIIa Antagonist
1999
Inhibition of hERG K+ currents by antimalarial drugs in stably transfected HEK293 cells
2003
Adverse effects of dipeptidyl peptidases 8 and 9 inhibition in rodents revisited
2008
Blinded Test in Isolated Female Rabbit Heart Reliably Identifies Action Potential Duration Prolongation and Proarrhythmic Drugs: Importance of Triangulation, Reverse Use Dependence, and Instability
2003
Are hERG channel inhibition and QT interval prolongation all there is in drug-induced torsadogenesis? A review of emerging trends
2005
Antiplatelet and Antithrombotic Efficacy of SR 121787, a Nonpeptide Orally Active GP IIb/IIIa Antagonist, in Rabbits: Comparison with Clopidogrel and Aspirin
1997
Investigation of the Potential of Clozapine to Cause Torsade de Pointes
2002
Scientific review and recommendations on preclinical cardiovascular safety evaluation of biologics
2008
Cardiac Safety Implications of hNav1.5 Blockade and a Framework for Pre-Clinical Evaluation
2012
Influence of Dietary Linoleic Acid on Cardiac Function and Prostaglandin Release and on the Effects of Isoprenaline in the Isolated Rat Heart
1982
The synthetic pentasaccharide SR 90107A/org 31540 enhances tissue-type plasminogen activator-induced thrombolysis in rabbits
1996
Perinatal linoleate deprivation impairs learning and memory in adult rats
1984
Toxicological Investigations in the Semiconductor Industry: I. Studies on the Acute Oral Toxicity of a Complex Mixture of Waste Products from the Aluminium Plasma Etching Process
1992
Serum triglycerides and HDL cholesterol from SHR after evening primrose oil and other polyunsaturated fats
1986
Antihypertensive action of dietary polyunsaturated fatty acids in spontaneously hypertensive rats.
1985
Comparative study of the blood pressure effects of four different vegetable fats on young, spontaneously hypertensive rats
1986
Biochemical and Pharmacological Properties of SANORG 34006, a Potent and Long-Acting Synthetic Pentasaccharide
1998
Antagonism of SR 90107A/Org 31540-lnduced Bleeding by Protamine Sulfate in Rats and Mice
1996
Arachidonic acid disrupts calcium dynamics in neonatal rat cardiac myocytes
1995
Toxicological Investigations in the Semiconductor Industry: II. Studies on the Subacute Inhalation Toxicity and Genotoxicity of Gaseous Waste Products from the Aluminium Plasma Etching Process
1992
Biochemical and Pharmacological Properties of SANORG 34006, a Potent and Long-Acting Synthetic Pentasaccharide
1998
Cardiovascular actions of dietary polyunsaturates and related mechanisms
1986